A review paper published in the Spring 2012 issue of European Respiratory Disease contends that, “Drug delivery to lungs with a consistent and predesigned ratio of co-associated active components can help maximise the chance of co-location at the active site and hence increases the potential of synergistic action from the solid.” Authored by Dipesh Parikh, David Hipkiss, and John Burns of Prosonix, Rob Price of the University of Bath, and Omar Usmani of Imperial College London, the article describes Prosonix’s method for engineering multi-component particles to create API-only combination formulations for inhalation.
Prosonix CEO Hipkiss commented, “The treatment of respiratory disease remains a high unmet need, despite the recent development of new therapies. The effective production and delivery of combination medicines in a consistent, stable and co-localised manner are lacking, given inefficiencies in current manufacturing and formulation processes. This paper highlights the potential for our engineered excipient-free, drug-only Multi-component Particles to deliver more effective and better tolerated respiratory medicines for patients.”
Read the full article.
Read the Prosonix press release.
